Dyne Therapeutics, Inc.

DYN

US26818M1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
41.48 ^USD	-6.05%		+4.88%	+211.88%

07-09	JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating	MT
07-01	Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Small Cap Comp Value Index	CI

Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 2000 Value Index

July 30, 2024

Latest news about Dyne Therapeutics, Inc.

JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating	07-09	MT
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Small Cap Comp Value Index	06-30	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000 Value Index	06-30	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Microcap Value Index	06-30	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Value Index	06-30	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Index	06-30	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Microcap Index	06-30	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 2500 Value Index	06-30	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 2000 Value Index	06-30	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Microcap Growth Index	06-30	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Growth Index	06-30	CI
Dyne Therapeutics Insider Sold Shares Worth $1,401,902, According to a Recent SEC Filing	06-25	MT
Dyne Therapeutics Insider Sold Shares Worth $1,334,201, According to a Recent SEC Filing	06-14	MT
Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress	06-13	CI
Dyne Therapeutics Insider Sold Shares Worth $2,583,782, According to a Recent SEC Filing	06-12	MT
Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing	05-23	MT
Dyne Therapeutics Prices $325.5 Million Common Stock Offering	05-22	MT
Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept	05-21	MT
Dyne Therapeutics Launches $300 Million Share Offering	05-20	MT
Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles	05-20	MT
HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating	05-20	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	05-20	MT
Transcript : Dyne Therapeutics, Inc. - Special Call	05-20
Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles	05-20	MT
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints	05-20	CI

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.15 USD

Average target price

46.3 USD

Spread / Average Target

+4.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DYNE THERAPEUTICS, INC.	+211.88%	4.38B
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research